 BEDFORD, Mass.-- BUSINESS WIRE --Stoke Therapeutics, Inc. Nasdaq: STOK, a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that seven abstracts related to the Companys work in Dravet syndrome have been accepted for presentation at the American Epilepsy Society AES 2022 Annual Meeting, taking place December 2 6, in Nashville, Tennessee. The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome. 